Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

Cited In for PubMed (Select 10929856)

1.

Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels.

Lamond NW, Skedgel C, Rayson D, Younis T.

Curr Oncol. 2015 Aug;22(4):e246-53. doi: 10.3747/co.22.2383.

2.

An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness.

Murphy SM, McDonell MG, McPherson S, Srebnik D, Angelo F, Roll JM, Ries RK.

Drug Alcohol Depend. 2015 Aug 1;153:293-9. doi: 10.1016/j.drugalcdep.2015.05.004. Epub 2015 May 14.

PMID:
26026494
3.

Cost-effectiveness of proton beam therapy for intraocular melanoma.

Moriarty JP, Borah BJ, Foote RL, Pulido JS, Shah ND.

PLoS One. 2015 May 18;10(5):e0127814. doi: 10.1371/journal.pone.0127814. eCollection 2015.

4.

Thresholds for the cost-effectiveness of interventions: alternative approaches.

Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S.

Bull World Health Organ. 2015 Feb 1;93(2):118-24. doi: 10.2471/BLT.14.138206. Epub 2014 Dec 15.

5.

A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?

Nimdet K, Chaiyakunapruk N, Vichansavakul K, Ngorsuraches S.

PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015.

6.

Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union.

Trasande L, Zoeller RT, Hass U, Kortenkamp A, Grandjean P, Myers JP, DiGangi J, Bellanger M, Hauser R, Legler J, Skakkebaek NE, Heindel JJ.

J Clin Endocrinol Metab. 2015 Apr;100(4):1245-55. doi: 10.1210/jc.2014-4324. Epub 2015 Mar 5.

7.

Cost-of-illness studies: concepts, scopes, and methods.

Jo C.

Clin Mol Hepatol. 2014 Dec;20(4):327-37. doi: 10.3350/cmh.2014.20.4.327. Epub 2014 Dec 24.

8.

Adaptive designs for subpopulation analysis optimizing utility functions.

Graf AC, Posch M, Koenig F.

Biom J. 2015 Jan;57(1):76-89. doi: 10.1002/bimj.201300257. Epub 2014 Nov 14.

9.

Economic evaluation of an area-wide integrated pest management program to control the Asian tiger mosquito in New Jersey.

Shepard DS, Halasa YA, Fonseca DM, Farajollahi A, Healy SP, Gaugler R, Bartlett-Healy K, Strickman DA, Clark GG.

PLoS One. 2014 Oct 22;9(10):e111014. doi: 10.1371/journal.pone.0111014. eCollection 2014.

10.

Current status of cost utility analyses in total joint arthroplasty: a systematic review.

Nwachukwu BU, Bozic KJ, Schairer WW, Bernstein JL, Jevsevar DS, Marx RG, Padgett DE.

Clin Orthop Relat Res. 2015 May;473(5):1815-27. doi: 10.1007/s11999-014-3964-4. Epub 2014 Sep 30. Review.

PMID:
25267271
11.

Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma.

Curl P, Vujic I, van 't Veer LJ, Ortiz-Urda S, Kahn JG.

PLoS One. 2014 Sep 8;9(9):e107255. doi: 10.1371/journal.pone.0107255. eCollection 2014.

12.

The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study.

van Hees F, Zauber AG, Klabunde CN, Goede SL, Lansdorp-Vogelaar I, van Ballegooijen M.

JAMA Intern Med. 2014 Oct;174(10):1568-76. doi: 10.1001/jamainternmed.2014.3889.

13.

Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.

Shah M, Dowdy D, Joloba M, Ssengooba W, Manabe YC, Ellner J, Dorman SE.

AIDS. 2013 Nov 28;27(18):2883-92. doi: 10.1097/QAD.0000000000000008.

14.

Relationship of meeting physical activity guidelines with quality-adjusted life-years.

Sun K, Song J, Manheim LM, Chang RW, Kwoh KC, Semanik PA, Eaton CB, Dunlop DD.

Semin Arthritis Rheum. 2014 Dec;44(3):264-70. doi: 10.1016/j.semarthrit.2014.06.002. Epub 2014 Jun 26.

PMID:
25074656
15.

Oral cancer therapy: policy implications for the uninsured and underinsured populations.

Faiman B.

J Adv Pract Oncol. 2013 Sep;4(5):354-60. Review. No abstract available.

16.

Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences.

Martín-Fernández J, Polentinos-Castro E, del Cura-González MI, Ariza-Cardiel G, Abraira V, Gil-LaCruz AI, García-Pérez S.

BMC Health Serv Res. 2014 Jul 3;14:287. doi: 10.1186/1472-6963-14-287.

17.

Cost-effectiveness of uterine-preserving procedures for the treatment of uterine fibroid symptoms in the USA.

Cain-Nielsen AH, Moriarty JP, Stewart EA, Borah BJ.

J Comp Eff Res. 2014 Sep;3(5):503-14. doi: 10.2217/cer.14.32. Epub 2014 May 30.

18.

Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.

Lamond NW, Younis T.

Int J Womens Health. 2014 May 16;6:509-21. doi: 10.2147/IJWH.S47357. eCollection 2014. Review.

19.

Surgical treatment for adult spinal deformity: projected cost effectiveness at 5-year follow-up.

Terran J, McHugh BJ, Fischer CR, Lonner B, Warren D, Glassman S, Bridwell K, Schwab F, Lafage V.

Ochsner J. 2014 Spring;14(1):14-22.

20.

Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009.

Goldman DP, Juday T, Seekins D, Linthicum MT, Romley JA.

Health Aff (Millwood). 2014 Mar;33(3):362-9. doi: 10.1377/hlthaff.2013.0830.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk